As our findings in NSCLC cell lines suggested concurrency of KRAS or BRAF and mutual exclusiveness of EGFR mutations with LKB1 mutations, we analysed the mutational status of these genes in our primary NSCLC tumour specimens. The gene discussed is BRAF; the disease is neoplasm.